Institutional members access full text with Ovid®

Share this article on:

Genomic rearrangements in prostate cancer

Barbieri, Christopher E.a,b,c; Rubin, Mark A.a,b,c,d

doi: 10.1097/MOU.0000000000000129
GENETIC TESTING OR BIOMARKERS FOR THE DETECTION OF PROSTATE CANCER: Edited by Daniel W. Lin
Editor's Choice

Purpose of review Genomic instability is a fundamental feature of human cancer, leading to the activation of oncogenes and inactivation of tumor suppressors. In prostate cancer (PCA), structural genomic rearrangements, resulting in gene fusions, amplifications, and deletions, are a critical mechanism effecting these alterations. Here, we review recent literature regarding the importance of genomic rearrangements in the pathogenesis of PCA and the potential impact on patient care.

Recent findings Next-generation sequencing has revealed a striking abundance, complexity, and heterogeneity of genomic rearrangements in PCA. These recent studies have nominated a number of processes in predisposing PCA to genomic rearrangements, including androgen-induced transcription.

Summary Structural rearrangements are the critical mechanism resulting in the characteristic genomic changes associated with PCA pathogenesis and progression. Future studies will determine whether the impact of these events on tumor phenotypes can be translated to clinical utility for patient prognosis and choices of management strategies.

aDepartment of Urology

bDepartment of Pathology and Laboratory Medicine

cSandra and Edward Meyer Cancer Center

dInstitute for Precision Medicine, Weill Cornell Medical College, New York, New York, USA

Correspondence to Christopher E. Barbieri, MD, PhD, Weill Cornell Medical College, 413 E. 69th Street, Room 1420, New York, NY 10021, USA. Tel: +1 646 962 6124; fax: +1 646 962 0576; e-mail: chb9074@med.cornell.edu

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.